Compare
Weight Loss

Semaglutide vs Tirzepatide

A practical comparison between a single GLP-1 receptor agonist and a dual GIP/GLP-1 agonist with deep human evidence.

Semaglutide

Weight Loss

Approved

Weight loss, type 2 diabetes, cardiovascular risk reduction

4,535 PubMed references2,607 human-tagged

Tirzepatide

Weight Loss

Approved

Weight loss, type 2 diabetes, dual GIP/GLP-1 agonist

1,942 PubMed references1,033 human-tagged

Side-by-side

SignalSemaglutideTirzepatide
Core mechanismGLP-1 receptor agonistDual GIP/GLP-1 receptor agonist
Research maturityApproved with broad cardiometabolic evidenceApproved with fast-expanding obesity, diabetes, and sleep-apnea evidence
Public conversationOften discussed around Wegovy/Ozempic access, plateaus, and GI effectsOften discussed around larger weight-loss expectations and access/cost

Sentiment Readout

Public discussion usually compares weight-loss magnitude, side effects, supply, insurance, and compounded access.

Regulatory Context

Both have FDA-approved products, but compounding and shortage policy can change how people encounter them.

Next Steps

Semaglutide detail Tirzepatide detail